Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 6 days ago
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

BMI a causal factor for osteoarthritis at weight-bearing joints

20 Oct 2019

High body mass index (BMI) is causally associated with the risk of osteoarthritis (OA) at the knee and hip but not at the hand, a study has found.

Researchers used data from the UK Biobank study involving 384,838 unrelated participants. They performed Mendelian randomization (MR) analyses to test for causality for BMI, bone mineral density (BMD), serum high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels, type 2 diabetes, systolic blood pressure (SBP), and C-reactive protein (CRP) levels.

A total of 48,431 participants had all-site OA, whereas 19,727 had knee OA, 11,875 had hip OA and 2,330 had hand OA. On MR analyses, genetically determined BMI had a strong causal association with all-site (odds ratio [OR] per standard deviation [SD] increase, 1.57, 95 percent CI, 1.44–1.71), knee (OR, 1.76, 1.56–1.99) and hip OA (OR, 1.52, 1.31–1.78) but not hand OA.

A similar pattern of association was observed between genetically determined femoral neck BMD and all-site (OR, 1.14, 1.06–1.22), knee (OR, 1.18, 1.05–1.32) and hip OA (OR, 1.22, 1.09–1.35) but not hand OA.

Low SBP was also causally associated with all-site (OR, 0.64, 0.54–0.77), knee (OR, 0.66, 0.57–0.77) and hip OA (OR, 0.63, 0.48–0.82). There was no evidence of causality for the other tested metabolic factors or CRP level.

The present data may be used for future investigations in OA, including the prevention or therapeutic strategies for the different OA locations, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.

Tristan Manalac, 3 days ago
Users of electronic nicotine delivery systems are likely to have received a diagnosis of clinical depression in the past, according to a recent study.
Pearl Toh, 6 days ago
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).